The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...

AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The collaboration aims to advance the discovery and development of novel oral candidates.

Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...